<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349778</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-05704</org_study_id>
    <secondary_id>97115</secondary_id>
    <secondary_id>BMT183</secondary_id>
    <nct_id>NCT00349778</nct_id>
  </id_info>
  <brief_title>High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma</brief_title>
  <official_title>High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to
      treat multiple myeloma. The study is being performed to evaluate the efficacy and side
      effects of treatment. Specifically, the study is designed to reduce the risk of interstitial
      pneumonitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analysis of 196 previously treated patients demonstrated a median event-free survival (EFS)
      of 36 months with a median overall survival of more than 6 years. The main toxicity of this
      therapy is related to carmustine-induced pneumonitis or interstitial pneumonitis (IP). This
      complication is related to the dose of carmustine. Institutional experience in myeloma
      patients using this dose of carmustine indicates an incidence of IP of34%.

      There have been recent studies evaluating the role of tandem autologous transplants for
      patients with multiple myeloma. These trials were based upon the hypothesis that performing
      tandem high-dose therapy regimens would lead to increased tumor cell kill, decreased tumor
      burden and an improvement in overall survival. Our results with high-dose sequential therapy
      including the dose-intense carmustine/melphalan transplant demonstrates similar median EFS
      and overall survival (OS) when compared with the results of tandem transplant approaches.The
      proposed trial will continue to use a high-dose sequential transplant approach, however, we
      will use a reduced dose of carmustine which we expect to be associated with a lower incidence
      of IP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Pulmonary Toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>Pulmonary toxicity was assessed as the incidence of interstitial pneumonitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Participant Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Survival status was assessed 5 years after transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Relapse After Autologous Transplantation</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse was measured as the number of patients who relapse after high-dose sequential therapy then autologous transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>High-Dose Sequential Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in ~250 mL of saline or D5W and infused IV over 2 hours</description>
    <arm_group_label>High-Dose Sequential Therapy</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>100 mg etoposide as 5 mL solution in clear ampules for injection.</description>
    <arm_group_label>High-Dose Sequential Therapy</arm_group_label>
    <other_name>Etopophos</other_name>
    <other_name>VePesid</other_name>
    <other_name>Toposar</other_name>
    <other_name>VP-16</other_name>
    <other_name>Etoposide phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.</description>
    <arm_group_label>High-Dose Sequential Therapy</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>Phenylalanine mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.</description>
    <arm_group_label>High-Dose Sequential Therapy</arm_group_label>
    <other_name>BiCNU</other_name>
    <other_name>BCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.</description>
    <arm_group_label>High-Dose Sequential Therapy</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Granulocyte-colony stimulating factor (G-CSF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Stage II to III multiple myeloma, or progression after initial treatment of Stage I
             disease; early or relapsed

          -  Age 18 to 75 years.

          -  Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.

          -  Patients with amyloidosis may be eligible for this trial, with approval by the
             Principle Investigator.

          -  Patients must have a Karnofsky performance status &gt; 70%.

          -  Aspartate aminotransferase (AST) must be &lt; 2 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) must be &lt; 2 x ULN

          -  Total bilirubin &lt; 2 mg/dL.

          -  Serum creatinine &lt; 2.0 or 24-hour creatinine clearance ≥ 60 mL/min.

          -  Patients must be HIV-negative.

          -  Patients must provide signed, informed consent.

        EXCLUSION CRITERIA

          -  Severe psychological or medical illness

          -  Prior autologous hematopoietic cell transplantation

          -  Pregnant

          -  Lactating women

          -  Smoldering multiple myeloma,

          -  Monoclonal gammopathy of unknown significance or primary amyloidosis will be excluded
             from this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally Arai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chen AI, Negrin RS, McMillan A, Shizuru JA, Johnston LJ, Lowsky R, Miklos DB, Arai S, Weng WK, Laport GG, Stockerl-Goldstein K. Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplant. 2012 Apr;47(4):516-21. doi: 10.1038/bmt.2011.106. Epub 2011 May 23.</citation>
    <PMID>21602899</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <results_first_submitted>April 26, 2017</results_first_submitted>
  <results_first_submitted_qc>November 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sally Arai</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-Dose Sequential Therapy</title>
          <description>Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>all patients who proceeded to transplant on trial</population>
      <group_list>
        <group group_id="B1">
          <title>High-Dose Sequential Therapy</title>
          <description>Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pulmonary Toxicity</title>
        <description>Pulmonary toxicity was assessed as the incidence of interstitial pneumonitis.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Sequential Therapy</title>
            <description>Cyclophosphamide + etoposide + melphalan + carmustine with filgrastim</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pulmonary Toxicity</title>
          <description>Pulmonary toxicity was assessed as the incidence of interstitial pneumonitis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Participant Survival (OS)</title>
        <description>Survival status was assessed 5 years after transplant.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Sequential Therapy</title>
            <description>Cyclophosphamide + etoposide + melphalan + carmustine with filgrastim</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Participant Survival (OS)</title>
          <description>Survival status was assessed 5 years after transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Relapse After Autologous Transplantation</title>
        <description>Relapse was measured as the number of patients who relapse after high-dose sequential therapy then autologous transplantation</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Sequential Therapy</title>
            <description>Cyclophosphamide + etoposide + melphalan + carmustine with filgrastim</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Relapse After Autologous Transplantation</title>
          <description>Relapse was measured as the number of patients who relapse after high-dose sequential therapy then autologous transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-Dose Sequential Therapy</title>
          <description>Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>aspergillus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Interstitial pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sally Arai</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-0822</phone>
      <email>sarai1@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

